Chemical Structure (Zunveyl 01)
Zunveyl Tablet, Delayed Release
Product Images NDC 84054-015
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Zunveyl (NDC 84054-015). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Alpha Cognition, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Zunveyl 02)
This is a description of a medication called Placebo, with a dosage of 8 to 16 mg per day. The text also mentions "Weeks of Treatment", suggesting that the medication is used for a specific period of time.*
Figure 2 (Zunveyl 03)
Figure 3 (Zunveyl 04)
Figure 4 (Zunveyl 05)
Figure 5 (Zunveyl 06)
This text provides information about the Cumulative Percentage of Patients based on different point values in a study involving a placebo, 24 mg/day, and 32 mg/day. It also includes data on the ADAS-cog Change From Baseline.*
Figure 6 (Zunveyl 07)
This text contains a list of words and phrases related to different levels of change or improvement, along with a reference to CIBIC-plus Rating. The list includes terms like Mukedly, Mpdertely, Mnimaly, Mnimally, Moderately, Meriedy, hpowed, Change, Wore, Worse, Improved, and Favored. The context or source of this list is not entirely clear.*
Figure 7 (Zunveyl 08)
Figure 8 (Zunveyl 09)
This text is a data set showing changes from a baseline in points. It includes both positive and negative values. The data ranges from -10 to 15 points. The term "ADAS-coq Change From Baseline" likely refers to a specific analysis or comparison related to the given data set.*
Figure 9 (Zunveyl 10)
This text appears to be a chart showing the percentage of patients falling under different categories of improvement based on the CIBIC-plus Rating scale. The categories seem to range from minimally improved to markedly improved, with some patients showing worsened conditions. The chart also includes the percentage of patients falling into these categories.*
Figure 10 (Zunveyl 11)
Not available.*
Figure 11 (Zunveyl 12)
Figure 12 (Zunveyl 13)
This text indicates a chart showing the percentage of patients categorized by different levels of improvement in a study. The categories range from "Markedly Improved" to "Worse" and are associated with different dosage levels labeled as "S Placebo." The data seems to be part of a CIBIC-plus rating evaluation.*
Principal Display Panel (5 mg Tablet Bottle Label)
This text provides information on the recommended dosage and storage instructions for benzgalantamine delayed-release tablets. Each tablet contains 5 mg of benzgalantamine freebase equivalent to 7.49 mg of benzgalantamine gluconate. The tablets are child-resistant and should be stored between 20°C to 25°C (66°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F). The product is manufactured for Alpha Cognition, Inc. For more resources, patients can visit Zunveyl.com or call 1-877-257-4203. The tablets are available in a pack of 60 tablets with the NDC code 84054-005-60 and are available by prescription only.*
Principal Display Panel (10 mg Tablet Bottle Label)
Recommended Dosage: Y NDC 8405401060 NDC: 3405401060 Read full prescribing information Rx Only. This package is child-resistant. Keep this and all EXPMM medicines out of sight and reach of children. Store at 20°C to 25°C (66°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) (benzgalantamine). Each tablet contains 10 mg benzgalantamine DELAYED RELEASE TABLETS. Manufactured for Alpha Pharmaceuticals, Ir (fioren60 Tablets). For patient Resources visit Zunveyl.com.*
Principal Display Panel (15 mg Tablet Bottle Label)
The provided text is a label of medication named ZUNVEYL (benzgalantamine) Delayed Release Tablets, with a recommended dosage of 15 mg per tablet containing benzgalantamine. It is advised to store between 20°C to 25°C (66°F to 77°F). The medication is child-resistant and should be kept out of sight and reach of children. The packaging contains 60 tablets. For full prescribing information, one can visit Zunveyl.com or call 1-677-257-4203.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
